Do yourself a favor and ask your mum to confiscate your computer. See a shrink. No one reads your one liners except when forced to during a page refresh. You are on IGNORE by everyone and his Dog.
But even so your endless meaningless posts take up a lot of greyed out space here.
Try to get some real friends in the real world to communicate with instead of communicating AT, not with a bunch of ID's on a board that you do not know. Seek Help.
whogo icantrade gaspasser,
Why would you have a copy of the Mylan injector instructions with you when you take the Teva injector out of the package. Would you not check on the instructions that cams with what you are holding in your hand?
The suicide was interesting, The guy actually stood on the injector and leaped to his death. He was wearing Nike running shoes. Due to this unfortunate event all Antares injectors and all Nike footwear will be banned.
OTREXUP is Slowly but Surely edging towards profitability.
Ferring is preparing for an imminent GLOBAL launch of ZOMA-Jet™.
Suma FDA A/B Generic approved and will be released mid year Sold by TEVA on a 50/50 profit split.
QST FDA NDA FILING ANTICIPATED THIS YEAR.
EPI A/B APPROVAL AND LAUNCH ANTICIPATED THIS YEAR.
And here we are at 1.08 Dollar per share?
At the end Q3 they had 50MM cash on hand that's at least 10Q with decreasing burn rate considering OTREXUP going up(flat last Q) Probable increase in injector sales with added second line at the beginning of Q4. Hopefully meaninful increase in Otrexup sales(December indicator+company statement) Sumatriptan launch Jul1....... and be and behold EPI the big elephant in the room. they will surely be making money by the end of the year with just OTREXUP and SUMA
The only one that can comment on any CRL to Teva is obviously Teva. Regardless of whats in the CRL if there is one, no other entity can comment on it's content unless Teva does so. I don't understand how you people can expect that ATRS somehow should be in a position to say anything since nothing has come out from Teva. EPI is a TEVA Product.
Who is lying about what? What he said was that there is no injector problem. If there would be Teva would surely have told them but that does not seem to be the case. Apparently there is no injector problem according to Howarth, do you have a problem with that? Where is the lie?
If you are not comfortable with the company,pipeline,management,posters....etc....
Then you should probably go and find another stock and board to post on. Since you are obviously wasting your own time here.
One final under-$10 specialty pharmaceutical player that's starting to spike within range of triggering a major breakout trade is Antares Pharma (ATRS - Get Report) , which that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. This stock has been hit hard by the sellers over the last six months, with shares falling big by 41.1%.
If you take a glance at the chart for Antares Pharma, you'll notice that this stock has been downtrending badly over the last six months, with shares falling sharply off its high of around $2.50 a share to its new 52-week low of $1.22 a share. During that downtrend, this stock has been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of Antares Pharma spiked modestly higher on Wednesday right above some near-term support at $1.28 a share with monster upside volume flows. Volume for that day registered over 3.76 million shares, which is easily above its three-month average action of 818,214 a shares. That high-volume spike to the upside is now quickly pushing this stock within range of triggering a major breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in Antares Pharma if it manages to break out above its 20-day moving average of $1.35 a share and then above more key resistance levels at $1.40 to its 50-day moving average of $1.48 a share and then over $1.51 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 818,214 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.71 to $2.03, or even its 200-day moving average of $2.09 to $2.25 a share.
Must Read: 5 Energy Stocks to Buy to Fuel Your Portfolio
Traders can look to buy shares of Antares Pharma off w
By the way they are still winners but I guess andre did not post to sell at the peak, then he should not use the peak numbers to highlight his excellence.
And that means they still Expect EPI from TEVA.
They would not poke FDA in the Eye with a burning stick if they do not expect serious competition.
Tayppy posts what once every three weeks on average and he points out what he believes is the positive potential of the company's portfolio.
And a whole bunch of posters gets their knickers in a twist.
Others post daily the same negative rehash of the same issue they have, with less variety than daviscupper and he's endless trivia, but he can actually be funny on occasion and at least he tries to vary his one liners.
And everyone seems ok with that?
Then again, it's the same knickers that gets in a twist that also seems to be most eager to re-hash their own negative opinion.
And the conclusion is
""Thus, current evidence suggests that the choice of MTX route of administration is a fundamental
parameter for optimizing RA treatment. The SC route of administration seems to be the best
treatment option from the outset, in terms of risk:benefit ratio compared with the oral route.
Finally, although to date there are no real evidence of cost-effectiveness of MTX SC versus
MTC OR, it is possible to assume that delaying the use of more aggressive and more expensive
therapies, such as bDMARDs, by switching from MTX OR to MTX SC in non-responders might
provide cost savings while reducing risks, with relevant implications in the everyday clinical
care of patients with RA. In this regard, a specifically designed study to assess this
outcome would be desirable.""
Are you suggesting that one injector can pass on it's flaws to other types of injectors(like influenza). If that is the case FDA will have to take a closer look at the current Mylan injector and every other injector on the market. In fact they better ban all injectors at once just in case.......
How do we know that? Are you the seer here?
The guy said he suspects that FDA will issue a CRL in December to buy some more time due to their backlog.
But he does not know if they will, how do you know?
Not because there are any outstanding issues, I think Teva has reiterated the fact that there are no outstanding EPI issues on presentation made after the CC.